2026-09-09 · 💊 FDA / Trial
Why is IRD stock up today?
Opus Genetics, Inc. Common Stock · IRD · updated 2026-09-09
PRICE$5.73
CHANGE+32.0%
VOLUME54.3M
6-DAY
In plain English
Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Up — GlobeNewswire Inc..
What it means for you
Finished the day strong — closed near its highs on heavy volume. Risk level: moderate.
Source: GlobeNewswire Inc.: Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences (2026-09-02)
About Opus Genetics, Inc. Common Stock
Market cap$476.7M
ExchangeXNAS
Employees28
HQDURHAM, NC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional ca
Get moves like this before the bell
Free daily email — the biggest movers, explained. No spam.
Not financial advice. Educational only. AI-assisted summary — verify against the linked source. Data may be delayed.